权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

SBIR Phase II: Developing suspended microchannel resonators as a platform for personalized medicine in cancer

SBIR 第二阶段：开发悬浮式微通道谐振器作为癌症个性化医疗的平台

基本信息

批准号：
2026060
负责人：
Selim Olcum
金额：
$ 100万
依托单位：
TRAVERA, INC.
依托单位国家：
美国
项目类别：
Cooperative Agreement
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-15 至 2022-12-31
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=2026060&HistoricalAwards=false
关键词：
SBIR Phase II Developing suspended

项目摘要

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to identify potential therapies for a multiple myeloma (MM) patients. Newly diagnosed MM is typically sensitive to a variety of therapies, but relapse is common in later stages. Personalized analysis would improve treatment decisions. This project will develop new testing for personalized medicine. Although the initial target is MM, this can potentially be applied to other cancers or diseases. Personalized medicine can lead to reduced healthcare costs, optimized drug development, and improved patient care.This Small Business Innovation Research (SBIR) Phase II project will help develop methods and techniques that will be used to offer new tests for guiding the treatment of multiple myeloma (MM) patients. The test relies on resolving changes of cancer cells collected from patients upon exposure to various drug options by measuring the mass of individual cells. Today MM is the second most common hematologic malignancy in the world. Unfortunately, today there are no biomarkers to define therapeutic susceptibility of MM patients to identify a personalized treatment regimen. This project aims to address this problem by developing a high-throughput single-cell mass measurement platform based on suspended microchannel resonators (SMR) to resolve the effects of the drugs on the cancer cells. In this project a new generation of SMR chips with linked single-cell imaging, image processing and cell classification will be developed to analyze a 20-drug panel in three hours.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

小企业创新研究(SBIR)第二阶段项目的更广泛影响/商业潜力是确定多发性骨髓瘤(MM)患者的潜在治疗方法。新诊断的多发性骨髓瘤通常对各种治疗方法敏感，但在后期复发很常见。个性化分析将改善治疗决策。该项目将为个性化药物开发新的测试。虽然最初的目标是多发性骨髓瘤，但这可能适用于其他癌症或疾病。个性化药物可以降低医疗成本，优化药物开发，改善患者护理。这个小型企业创新研究(SBIR)第二阶段项目将帮助开发方法和技术，用于提供新的测试，以指导多发性骨髓瘤(MM)患者的治疗。这项测试依赖于通过测量单个细胞的质量来解决从患者那里收集的癌细胞在暴露于各种药物选项时的变化。今天，MM是世界上第二常见的血液系统恶性肿瘤。不幸的是，今天还没有生物标志物来定义多发性骨髓瘤患者的治疗敏感性，以确定个性化的治疗方案。本项目旨在解决这一问题，开发一种基于悬浮微通道谐振器(SMR)的高通量单细胞质量测量平台，以解决药物对癌细胞的影响。在这个项目中，新一代SMR芯片将被开发出来，结合单细胞成像、图像处理和细胞分类，在三个小时内分析一个由20种药物组成的小组。这一奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。